Jasper Therapeutics (JSPR), announced that the first patient has been dosed in Jasper’s Phase 1b/2a clinical challenge study evaluating briquilimab in allergic asthma, called ETESIAN,Evaluating The ...

REDWOOD CITY, Calif., June 14, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody ...

Jasper Therapeutics, Inc. JSPR announced the FDA clearance of its investigational new drug application to begin a phase Ib/IIa study of subcutaneous (SC) briquilimab, the company’s lead pipeline ...